Comparative Pharmacology
Head-to-head clinical analysis: CEFACLOR versus TAZICEF.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFACLOR versus TAZICEF.
CEFACLOR vs TAZICEF
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Bactericidal; inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), disrupting peptidoglycan cross-linking.
Ceftazidime is a third-generation cephalosporin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBP-3, leading to cell lysis and death.
250-500 mg orally every 8 hours
2 g intravenously every 8 hours for serious infections; 1 g intravenously every 8 hours for uncomplicated infections.
None Documented
None Documented
Terminal elimination half-life: 0.5-1 hour; prolonged to 2-3 hours in renal impairment
Clinical Note
moderateCefaclor + Probenecid
"The serum concentration of Probenecid can be increased when it is combined with Cefaclor."
Clinical Note
moderateCefaclor + Picosulfuric acid
"The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Cefaclor."
Clinical Note
moderateWarfarin + Cefaclor
"Warfarin may increase the anticoagulant activities of Cefaclor."
Clinical Note
moderatePhenprocoumon + Cefaclor
2 hours (prolonged to 4-12 hours in renal impairment; anuria: 20-30 hours).
Renal: 60-85% unchanged in urine within 8 hours; biliary/fecal: minor, ~5%
Primarily renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal <10%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic
"Phenprocoumon may increase the anticoagulant activities of Cefaclor."